Citadel Advisors
ABEO icon

Citadel Advisors’s Abeona Therapeutics ABEO Stock Holding History

Citadel Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Sell
55,837
-71,781
-56% -$359K ﹤0.01% 10910
2025
Q4 		$673K Sell
127,618
-145,828
-53% -$734K ﹤0.01% 8291
2025
Q3 		$1.44M Buy
+273,446
New +$1.73M ﹤0.01% 6744
2025
Q2 		– Sell
-32,044
Closed -$182K – 12306
2025
Q1 		$153K Buy
32,044
+30,762
+2,400% +$167K ﹤0.01% 10850
2024
Q4 		$7.14K Buy
1,282
+573
+81% +$3.53K ﹤0.01% 13751
2024
Q3 		$4.48K Sell
709
-3,521
-83% -$18.4K ﹤0.01% 13562
2024
Q2 		$17.9K Buy
4,230
+4,226
+105,650% +$21.6K ﹤0.01% 12732
2024
Q1 		$29 Sell
4
-91,116
-100% -$577K ﹤0.01% 14447
2023
Q4 		$457K Buy
+91,120
New +$401K ﹤0.01% 8303
2022
Q2 		– Sell
-3,759
Closed -$29K – 12754
2022
Q1 		$29K Sell
3,759
-9,549
-72% -$65.6K ﹤0.01% 13117
2021
Q4 		$112K Buy
+13,308
New +$244K ﹤0.01% 12601
2021
Q3 		– Sell
-2,143
Closed -$83K – 13708
2021
Q2 		$83K Sell
2,143
-4,821
-69% -$197K ﹤0.01% 13049
2021
Q1 		$327K Sell
6,964
-107,874
-94% -$5.94M ﹤0.01% 10637
2020
Q4 		$4.51M Buy
114,838
+73,844
+180% +$2.52M ﹤0.01% 3861
2020
Q3 		$1.04M Sell
40,994
-17,466
-30% -$1.1M ﹤0.01% 5951
2020
Q2 		$4.26M Buy
58,460
+3,846
+7% +$266K ﹤0.01% 3310
2020
Q1 		$2.87M Buy
54,614
+38,603
+241% +$2.58M ﹤0.01% 3530
2019
Q4 		$1.31M Buy
16,011
+1,998
+14% +$141K ﹤0.01% 5105
2019
Q3 		$792K Sell
14,013
-6,848
-33% -$513K ﹤0.01% 5990
2019
Q2 		$2.49M Buy
+20,861
New +$3.5M ﹤0.01% 4145
2018
Q4 		– Sell
-1,596
Closed -$348K – 9005
2018
Q3 		$511K Buy
1,596
+257
+19% +$91.2K ﹤0.01% 6653
2018
Q2 		$536K Sell
1,339
-63,897
-98% -$27.9M ﹤0.01% 6253
2018
Q1 		$23.4M Buy
65,236
+64,733
+12,869% +$24.1M 0.01% 1006
2017
Q4 		$199K Sell
503
-56,950
-99% -$23.6M ﹤0.01% 7122
2017
Q3 		$24.5M Buy
+57,453
New +$15.4M 0.02% 942
2017
Q1 		– Sell
-654
Closed -$79K – 7364
2016
Q4 		$79K Buy
+654
New +$102K ﹤0.01% 6755

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ABEO Position: Q1 2026 in Review

Citadel Advisors reduced its Abeona Therapeutics (ABEO) stake by 56% in Q1 2026, selling an estimated $359K and leaving 55,837 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #10910.

Citadel Advisors first reported a position in ABEO in Q4 2016 and has held it in 26 quarters since. The position peaked at $24.5M in Q3 2017. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Citadel Advisors held 55,837 shares of Abeona Therapeutics worth $250K as of Q1 2026.
  • Citadel Advisors sold 71,781 Abeona Therapeutics shares in Q1 2026, an estimated $359K.
  • Abeona Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10910 holding.
  • Citadel Advisors first reported a position in Abeona Therapeutics in Q4 2016 and has held it in 26 quarters since.
  • Citadel Advisors's Abeona Therapeutics position peaked at $24.5M in Q3 2017.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.